Axsome Therapeutics, Inc. financial data

Symbol
AXSM on Nasdaq
Industry
Pharmaceutical Preparations
Location
One World Trade Center, 22 Nd Floor, New York, NY
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2024 - Nov 12, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 286 % -22.7%
Quick Ratio 9.04 % +22.6%
Debt-to-equity 323 % +113%
Return On Equity -234 % -123%
Return On Assets -55.4 % -32.8%
Operating Margin -90.5 %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 48.5M shares +2.42%
Common Stock, Shares, Outstanding 48.4M shares +2.36%
Entity Public Float 2.8B USD +133%
Common Stock, Value, Issued 5K USD 0%
Weighted Average Number of Shares Outstanding, Basic 48.1M shares +2.17%
Weighted Average Number of Shares Outstanding, Diluted 48.1M shares +2.17%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 338M USD +81.3%
Cost of Revenue 1.9M USD
Research and Development Expense 163M USD +99%
General and Administrative Expense 81.1M USD +131%
Costs and Expenses 645M USD +54.6%
Operating Income (Loss) -306M USD -58.3%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -311M USD -55.2%
Income Tax Expense (Benefit) -325K USD
Net Income (Loss) Attributable to Parent -311M USD -54.1%
Earnings Per Share, Basic -6.6 USD/shares -45.7%
Earnings Per Share, Diluted -6.6 USD/shares -45.7%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 327M USD -21.4%
Accounts Receivable, after Allowance for Credit Loss, Current 124M USD +58.3%
Inventory, Net 14.3M USD +42.9%
Assets, Current 479M USD -6.38%
Property, Plant and Equipment, Net 683K USD -29.7%
Operating Lease, Right-of-Use Asset 5.73M USD -18.9%
Intangible Assets, Net (Excluding Goodwill) 48.5M USD -11.6%
Goodwill 12M USD 0%
Other Assets, Noncurrent 507K USD +59.9%
Assets 561M USD -6.56%
Accounts Payable, Current 64.3M USD +121%
Employee-related Liabilities, Current 19.4M USD +33.7%
Liabilities, Current 196M USD +71.1%
Operating Lease, Liability, Noncurrent 6.44M USD -16.3%
Liabilities 469M USD +41.4%
Retained Earnings (Accumulated Deficit) -1.05B USD -42.2%
Stockholders' Equity Attributable to Parent 92.9M USD -65.5%
Liabilities and Equity 561M USD -6.56%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -53.5M USD -819%
Net Cash Provided by (Used in) Financing Activities -1.19M USD -102%
Net Cash Provided by (Used in) Investing Activities -98K USD -38%
Common Stock, Shares Authorized 150M shares 0%
Common Stock, Shares, Issued 48.4M shares +2.36%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -54.8M USD -220%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 327M USD -21.4%
Interest Paid, Excluding Capitalized Interest, Operating Activities 4.9M USD +52.5%
Deferred Tax Assets, Valuation Allowance 223M USD +21.2%
Deferred Tax Assets, Gross 225M USD +22%
Operating Lease, Liability 8.07M USD -0.76%
Depreciation 132K USD +46.7%
Payments to Acquire Property, Plant, and Equipment 98K USD +38%
Lessee, Operating Lease, Liability, to be Paid 10.5M USD -9.45%
Operating Lease, Liability, Current 1.63M USD +271%
Lessee, Operating Lease, Liability, to be Paid, Year Two 2.52M USD +2.81%
Lessee, Operating Lease, Liability, to be Paid, Year One 1.98M USD +174%
Operating Lease, Weighted Average Discount Rate, Percent 0.12 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 2.4M USD -30%
Lessee, Operating Lease, Liability, to be Paid, Year Three 2.52M USD 0%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 3.2M USD +27.1%
Preferred Stock, Shares Outstanding 0 shares
Amortization of Intangible Assets 6.39M USD -0.06%
Share-based Payment Arrangement, Expense 18.1M USD -60.1%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%